QLS2313

· Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for QLS2313, covering 2025-12-19 to 2025-12-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies [Phase 1]